DC Vaccination for Post-remission Therapy in AML

Summary

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients. Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Timeline

Start

2015-03

Primary completion

2019-11

Completion

2019-11

Drugs

Indications